Trial Outcomes & Findings for A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT NCT02158858)
NCT ID: NCT02158858
Last Updated: 2026-06-04
Results Overview
A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed by the Investigator as unrelated to disease progression, intercurrent illness, or concomitant medications that occurred within the first cycle of treatment (21-day cycle) with pelabresib (CPI-0610), and that met any of the criteria specified in the protocol.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
336 participants
Primary outcome timeframe
Up to 21 days
Results posted on
2026-06-04
Participant Flow
This study was conducted at 54 centers across 9 countries (Belgium, Canada, France, Germany, Italy, Netherlands, Poland, United Kingdom, United States)
Not completed = Participants who discontinued study treatment
Participant milestones
| Measure |
Phase 1 (24 mg Capsule PO Daily)
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1A
In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1B
In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2A
In Phase 2 (Arm 2) - Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2B
In Phase 2 (Arm 2) - Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 3 (Combination Treatment Arm for JAKi-Naïve MF Participants)
Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily.
Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 4 (Monotherapy Arm for Essential Thrombocythemia (ET))
Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
5
|
5
|
3
|
3
|
4
|
7
|
8
|
6
|
48
|
52
|
59
|
28
|
84
|
21
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
3
|
5
|
5
|
3
|
3
|
4
|
7
|
8
|
6
|
48
|
52
|
59
|
28
|
84
|
21
|
Reasons for withdrawal
| Measure |
Phase 1 (24 mg Capsule PO Daily)
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1A
In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1B
In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2A
In Phase 2 (Arm 2) - Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2B
In Phase 2 (Arm 2) - Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 3 (Combination Treatment Arm for JAKi-Naïve MF Participants)
Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily.
Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 4 (Monotherapy Arm for Essential Thrombocythemia (ET))
Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Disease progression
|
1
|
3
|
3
|
2
|
3
|
2
|
3
|
1
|
0
|
5
|
9
|
13
|
7
|
12
|
1
|
|
Overall Study
Adverse Event
|
0
|
1
|
1
|
1
|
0
|
2
|
1
|
3
|
1
|
10
|
7
|
17
|
6
|
14
|
4
|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
3
|
2
|
5
|
8
|
6
|
3
|
10
|
4
|
|
Overall Study
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
4
|
3
|
4
|
1
|
8
|
0
|
|
Overall Study
Other protocol defined stopping criteria
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
2
|
1
|
0
|
2
|
3
|
0
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
2
|
20
|
13
|
14
|
6
|
10
|
3
|
|
Overall Study
Transitioned to pelabresib extension study
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
7
|
3
|
0
|
14
|
9
|
|
Overall Study
Cell transplant
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
2
|
3
|
13
|
0
|
Baseline Characteristics
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Baseline characteristics by cohort
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=3 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=5 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=5 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=3 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=3 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=4 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
n=7 Participants
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
n=8 Participants
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
n=6 Participants
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1A
n=48 Participants
In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1B
n=52 Participants
In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2A
n=59 Participants
In Phase 2 (Arm 2) - Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2B
n=28 Participants
In Phase 2 (Arm 2) - Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 3 (Combination Treatment Arm for JAKi-Naïve MF Participants)
n=84 Participants
Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily.
Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 4 (Monotherapy Arm for Essential Thrombocythemia (ET))
n=21 Participants
Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Total
n=336 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
79.0 Years
n=9 Participants
|
65.0 Years
n=27 Participants
|
69.0 Years
n=267 Participants
|
76.0 Years
n=265 Participants
|
80.0 Years
n=568 Participants
|
66.5 Years
n=22 Participants
|
63.0 Years
n=23 Participants
|
65.5 Years
n=22 Participants
|
61.0 Years
n=178 Participants
|
73.0 Years
n=116 Participants
|
69.5 Years
n=2 Participants
|
72.0 Years
n=4 Participants
|
65.5 Years
n=190 Participants
|
68.0 Years
n=19 Participants
|
64.0 Years
n=18 Participants
|
69.1 Years
n=18 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=9 Participants
|
1 Participants
n=27 Participants
|
1 Participants
n=267 Participants
|
3 Participants
n=265 Participants
|
1 Participants
n=568 Participants
|
0 Participants
n=22 Participants
|
2 Participants
n=23 Participants
|
1 Participants
n=22 Participants
|
2 Participants
n=178 Participants
|
16 Participants
n=116 Participants
|
29 Participants
n=2 Participants
|
18 Participants
n=4 Participants
|
13 Participants
n=190 Participants
|
25 Participants
n=19 Participants
|
13 Participants
n=18 Participants
|
128 Participants
n=18 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=9 Participants
|
4 Participants
n=27 Participants
|
4 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
2 Participants
n=568 Participants
|
4 Participants
n=22 Participants
|
5 Participants
n=23 Participants
|
7 Participants
n=22 Participants
|
4 Participants
n=178 Participants
|
32 Participants
n=116 Participants
|
23 Participants
n=2 Participants
|
41 Participants
n=4 Participants
|
15 Participants
n=190 Participants
|
59 Participants
n=19 Participants
|
8 Participants
n=18 Participants
|
208 Participants
n=18 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
0 Participants
n=568 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=178 Participants
|
0 Participants
n=116 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=190 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=9 Participants
|
1 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
0 Participants
n=568 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=178 Participants
|
1 Participants
n=116 Participants
|
1 Participants
n=2 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=190 Participants
|
3 Participants
n=19 Participants
|
0 Participants
n=18 Participants
|
8 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
0 Participants
n=568 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=178 Participants
|
0 Participants
n=116 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=190 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=18 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
1 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
0 Participants
n=568 Participants
|
1 Participants
n=22 Participants
|
1 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
2 Participants
n=178 Participants
|
4 Participants
n=116 Participants
|
1 Participants
n=2 Participants
|
2 Participants
n=4 Participants
|
4 Participants
n=190 Participants
|
3 Participants
n=19 Participants
|
0 Participants
n=18 Participants
|
19 Participants
n=18 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=9 Participants
|
4 Participants
n=27 Participants
|
4 Participants
n=267 Participants
|
3 Participants
n=265 Participants
|
3 Participants
n=568 Participants
|
1 Participants
n=22 Participants
|
6 Participants
n=23 Participants
|
8 Participants
n=22 Participants
|
4 Participants
n=178 Participants
|
42 Participants
n=116 Participants
|
47 Participants
n=2 Participants
|
54 Participants
n=4 Participants
|
22 Participants
n=190 Participants
|
75 Participants
n=19 Participants
|
19 Participants
n=18 Participants
|
295 Participants
n=18 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
0 Participants
n=568 Participants
|
2 Participants
n=22 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=178 Participants
|
1 Participants
n=116 Participants
|
2 Participants
n=2 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=190 Participants
|
3 Participants
n=19 Participants
|
2 Participants
n=18 Participants
|
12 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
0 Participants
n=568 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=178 Participants
|
0 Participants
n=116 Participants
|
1 Participants
n=2 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=190 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=18 Participants
|
2 Participants
n=18 Participants
|
PRIMARY outcome
Timeframe: Up to 21 daysPopulation: Dose-limiting toxicity (DLT) population included all participants who received at least 85% of their planned dose of pelabresib (CPI-0610) in Cycle 1, unless interrupted by a DLT, and who had sufficient follow-up data to allow the investigators and sponsor to determine whether DLT occurred.
A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed by the Investigator as unrelated to disease progression, intercurrent illness, or concomitant medications that occurred within the first cycle of treatment (21-day cycle) with pelabresib (CPI-0610), and that met any of the criteria specified in the protocol.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=3 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=4 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=5 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=3 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=3 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=3 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
n=6 Participants
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
n=6 Participants
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
n=5 Participants
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Frequency of Dose-limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: Week 24 (Cycle 9 Day 1)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Splenic Response Rate (SVR35) at Week 24 was defined as the proportion of participants who demonstrated a reduction of at least 35% in spleen size from baseline, as measured by imaging techniques (MRI or CT), following 24 weeks of treatment.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=52 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=28 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=84 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at Week 24
|
19.2 Percentage of Participants
Interval 9.6 to 32.5
|
21.4 Percentage of Participants
Interval 8.3 to 41.0
|
67.9 Percentage of Participants
Interval 56.8 to 77.6
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Any 12 consecutive weeks (rolling window) during active treatment with pelabresib (CPI-0610), from first dose through treatment discontinuation (up to approximately 8 years for Phase II)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Conversion rate was defined as the proportion of participants who converted from transfusion dependence (TD) to transfusion independence (TI). TD was characterized by receiving an average of at least 2 units of red blood cell (RBC) transfusions per month-amounting to a minimum of 6 units over the 12 weeks prior to enrollment-while TI was defined as the absence of RBC transfusions during any consecutive 12-week period.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=59 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Cohorts 1A and 2A): Number of Participants Enrolled as Transfusion Dependent (TD) With Conversion Rate From Red Blood Cell (RBC) Transfusion Dependence (TD) to Transfusion Independence (TI)
|
25.6 Percentage of Participants
Interval 13.5 to 41.2
|
26.1 Percentage of Participants
Interval 14.3 to 41.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Complete Hematological Response (CHR) Rate was defined as the proportion of participants who fulfilled the criteria for CHR, based on the modified European LeukemiaNet (ELN) guidelines (Barosi et al 2009): platelet count ≤400 × 10⁹/L, white blood cell (WBC) count ≤10 × 10⁹/L, confirmation of laboratory values after one treatment cycle, and normal spleen size determined by palpation or imaging.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=21 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 4): Number of Participants With Complete Hematological Response (CHR) Rate
|
57.1 Percentage of Participants
Interval 34.0 to 78.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to approximately 6 monthsPopulation: Safety Analysis Set (SAF) included all participants who received at least one dose of study treatment.
The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=3 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=5 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=5 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=3 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=3 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=4 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
n=7 Participants
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
n=8 Participants
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
n=6 Participants
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any drug-related serious TEAEs
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any TEAEs leading to drug discontinuation
|
0 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
4 Participants
|
3 Participants
|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with at least 1 TEAE
|
3 Participants
|
5 Participants
|
5 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
7 Participants
|
8 Participants
|
6 Participants
|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with ≥ Grade 3 TEAEs
|
2 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
4 Participants
|
7 Participants
|
8 Participants
|
6 Participants
|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any drug-related TEAE
|
3 Participants
|
3 Participants
|
5 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
6 Participants
|
7 Participants
|
5 Participants
|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any drug-related TEAEs of ≥ CTCAE Grade 3
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
3 Participants
|
4 Participants
|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any serious TEAEs
|
1 Participants
|
4 Participants
|
3 Participants
|
1 Participants
|
2 Participants
|
4 Participants
|
6 Participants
|
6 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Up to approximately 387 weeksPopulation: Safety Analysis Set (SAF) included all participants who received at least one dose of study treatment.
The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=52 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=59 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=28 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=84 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=21 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with at least 1 TEAE related to pelabresib
|
45 Participants
|
44 Participants
|
53 Participants
|
27 Participants
|
74 Participants
|
20 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with ≥ Grade 3 TEAEs related to pelabresib
|
27 Participants
|
21 Participants
|
33 Participants
|
14 Participants
|
41 Participants
|
6 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any serious TEAEs related to pelabresib
|
4 Participants
|
3 Participants
|
2 Participants
|
6 Participants
|
16 Participants
|
2 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with at least 1 TEAE
|
48 Participants
|
51 Participants
|
59 Participants
|
28 Participants
|
84 Participants
|
21 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with ≥ Grade 3 TEAEs
|
38 Participants
|
40 Participants
|
49 Participants
|
21 Participants
|
66 Participants
|
10 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any serious TEAEs
|
18 Participants
|
23 Participants
|
29 Participants
|
18 Participants
|
40 Participants
|
5 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any TEAEs leading to interruption of pelabresib
|
20 Participants
|
16 Participants
|
32 Participants
|
13 Participants
|
39 Participants
|
9 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any TEAEs leading in reduction of pelabresib
|
16 Participants
|
10 Participants
|
15 Participants
|
7 Participants
|
38 Participants
|
6 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any TEAEs leading to discontinuation of pelabresib
|
12 Participants
|
12 Participants
|
17 Participants
|
7 Participants
|
22 Participants
|
3 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
Participants with any TEAEs leading to study discontinuation
|
11 Participants
|
11 Participants
|
18 Participants
|
9 Participants
|
22 Participants
|
5 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component. Only those participants contributing data at the indicated time point were analyzed.
The Patient Global Impression of Change (PGIC) was a single-question, patient-reported assessment that asked individuals to rate their overall change in myeloproliferative neoplasm (MPN) symptoms since starting study treatment. The participants selected one of seven options, ranging from 'Very much improved' to 'Very much worse'. 'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=39 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=43 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=47 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=25 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=80 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=19 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks
PGIC status at Week 12 · Improvement
|
28 Participants
|
36 Participants
|
22 Participants
|
18 Participants
|
66 Participants
|
13 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks
PGIC status at Week 12 · No change
|
7 Participants
|
2 Participants
|
15 Participants
|
4 Participants
|
9 Participants
|
4 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks
PGIC status at Week 12 · Worsening
|
4 Participants
|
5 Participants
|
10 Participants
|
3 Participants
|
5 Participants
|
2 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks
PGIC status at Week 24 · Improvement
|
20 Participants
|
29 Participants
|
27 Participants
|
16 Participants
|
58 Participants
|
8 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks
PGIC status at Week 24 · No change
|
10 Participants
|
3 Participants
|
12 Participants
|
6 Participants
|
15 Participants
|
3 Participants
|
—
|
—
|
—
|
|
Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks
PGIC status at Week 24 · Worsening
|
2 Participants
|
5 Participants
|
4 Participants
|
0 Participants
|
6 Participants
|
4 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component. Only those participants contributing data at the indicated time point were analyzed.
The MFSAF (Myelofibrosis Symptom Assessment Form) was completed by participants every day for 7 days before Day 1 of each treatment cycle, including the 7 days before starting Cycle 1. It used a 24-hour recall format, asking participants to rate the worst severity of seven symptoms (fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain) during the past 24 hours. Each symptom was rated on a scale from 0 (Absent) to 10 (Worst Imaginable). The Total Symptom Score (TSS) was the sum of 7 symptoms (range: 0-70). 'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=38 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=43 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=48 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=25 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=82 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arms 1, 2 and 3): Percent Change From Baseline in Total Symptom Score (TSS) From the Myelofibrosis Symptom Assessment Form (MFSAF v4.0) at 12 and 24 Weeks
Percent Change from baseline to Week 12
|
-38.77 Score on a scale
Standard Deviation 38.637
|
-30.98 Score on a scale
Standard Deviation 35.394
|
-27.18 Score on a scale
Standard Deviation 75.391
|
-29.70 Score on a scale
Standard Deviation 36.106
|
-39.91 Score on a scale
Standard Deviation 69.251
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arms 1, 2 and 3): Percent Change From Baseline in Total Symptom Score (TSS) From the Myelofibrosis Symptom Assessment Form (MFSAF v4.0) at 12 and 24 Weeks
Percent Change from baseline to Week 24
|
-32.69 Score on a scale
Standard Deviation 36.474
|
-39.82 Score on a scale
Standard Deviation 42.228
|
-38.93 Score on a scale
Standard Deviation 61.818
|
-44.73 Score on a scale
Standard Deviation 35.224
|
-47.43 Score on a scale
Standard Deviation 52.460
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
The proportion of study participants who experienced a reduction of at least 50% in their Total Symptom Score (TSS), as assessed using the Myelofibrosis Symptom Assessment Form (MFSAF v4.0), was evaluated at both 12 and 24 weeks relative to their baseline score.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=52 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=59 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=28 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=84 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arms 1, 2 and 3): Number of Participants Who Achieved a ≥ 50% Reduction in Total Symptom Score (TSS) at 12 and 24 Weeks
MFSAF TSS50 response at week 24
|
15.6 Percentage of Participants
Interval 6.5 to 29.5
|
34.7 Percentage of Participants
Interval 21.7 to 49.6
|
36.2 Percentage of Participants
Interval 24.0 to 49.9
|
40.7 Percentage of Participants
Interval 22.4 to 61.2
|
56.1 Percentage of Participants
Interval 44.7 to 67.0
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arms 1, 2 and 3): Number of Participants Who Achieved a ≥ 50% Reduction in Total Symptom Score (TSS) at 12 and 24 Weeks
MFSAF TSS50 response at week 12
|
33.3 Percentage of Participants
Interval 20.0 to 49.0
|
31.3 Percentage of Participants
Interval 18.7 to 46.3
|
36.2 Percentage of Participants
Interval 24.0 to 49.9
|
33.3 Percentage of Participants
Interval 16.5 to 54.0
|
52.4 Percentage of Participants
Interval 41.1 to 63.6
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Through Phase II completion, an average of 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Overall Splenic Response Rate (SVR35) was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), at any point between Cycle 1 Day 1 and the End of Study Visit, whichever occurred first.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=52 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=59 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=28 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=84 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arms 1, 2 and 3): Number of Participants With Overall Splenic Response Rate (Overall SVR35)
|
16.7 Percentage of Participants
Interval 7.0 to 31.4
|
28.8 Percentage of Participants
Interval 17.1 to 43.1
|
30.8 Percentage of Participants
Interval 18.7 to 45.1
|
25.0 Percentage of Participants
Interval 10.7 to 44.9
|
79.8 Percentage of Participants
Interval 69.6 to 87.7
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From first onset of splenic response until loss of response, assessed up to approximately 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Duration of Overall Splenic Response (overall SVR35) was defined as the time from the first occurrence of a at least 35% reduction in spleen volume from baseline until the earliest of the following: a reduction of less than 35% from baseline combined with an increase of more than 25% from the nadir in spleen volume (as measured by MRI or CT), or death. The nadir was defined as the lowest spleen volume recorded after baseline and up to the evaluation point at which the initial splenic response was achieved.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=52 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=59 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=28 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=84 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arms 1, 2 and 3): Duration of Overall Splenic Response (Overall SVR35)
|
24.1 Weeks
Interval 12.4 to
NA: Not estimable due to insufficient number of participants with events
|
73.1 Weeks
Interval 27.1 to 106.4
|
180.9 Weeks
Interval 73.0 to
NA: Not estimable due to insufficient number of participants with events
|
228.4 Weeks
Interval 36.1 to
NA: Not estimable due to insufficient number of participants with events
|
197.6 Weeks
Interval 95.7 to
NA: Not estimable due to insufficient number of participants with events
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Splenic Response Rate (SVR35) at 12 and 24 weeks was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as determined by imaging (MRI or CT), following 12 and 24 weeks of treatment, respectively.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=59 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Cohorts 1A and 2A): Number of Participants With Splenic Response Rate (SVR35) at 12 and 24 Weeks
SVR35 at week 12
|
9.3 Percentage of Participants
Interval 2.6 to 22.1
|
9.4 Percentage of Participants
Interval 3.1 to 20.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Cohorts 1A and 2A): Number of Participants With Splenic Response Rate (SVR35) at 12 and 24 Weeks
SVR35 at week 24
|
0 Percentage of Participants
Interval 0.0 to
Not Applicable = Not calculated due to insufficient number of participants with events.
|
16.4 Percentage of Participants
Interval 7.8 to 28.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From first onset of TI to earliest onset of loss of TI, assessed up to approximately 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Duration of Red Blood Cell (RBC) Transfusion Independence (TI) was defined as the longest continuous period during which participants, having achieved at least 12 weeks of transfusion independence, remained free from RBC transfusions.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=59 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Cohorts 1A and 2A): Duration of Red Blood Cell (RBC) Transfusion Independence (TI) in Participants Who Enroll as Transfusion Dependent (TD)
|
35.8 Weeks
Interval 15.3 to
NA: Not estimable due to insufficient number of participants with events
|
68.0 Weeks
Interval 34.7 to
NA: Not estimable due to insufficient number of participants with events
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Through Phase II completion, an average of 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Early anemic response rate was defined as the proportion of participants who achieved an average increase of at least 1 g/dL in hemoglobin concentration over any rolling 8-week (56-day) period following baseline. This calculation was performed after applying the 14/3 day rule, which stipulates that hemoglobin measurements must be spaced at least 14 days apart, and that at least 3 such measurements are required within the 8-week window to ensure a reliable average. Importantly, this increase had to occur without any red blood cell (RBC) transfusions during the treatment period and up to the time of the latest hemoglobin assessment for each patient.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=48 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=59 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Cohorts 1A and 2A): Early Anemic Response Rate in Participants Who Enroll as Transfusion Dependent (TD)
|
18.6 Percentage of Participants
Interval 8.4 to 33.4
|
21.7 Percentage of Participants
Interval 10.9 to 36.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Week 12 (Cycle 5 Day 1)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Splenic Response Rate (SVR35) at Week 12 was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), following 12 weeks of treatment.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=52 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=28 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=84 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at 12 Weeks
|
15.4 Percentage of Participants
Interval 6.9 to 28.1
|
10.7 Percentage of Participants
Interval 2.3 to 28.2
|
66.7 Percentage of Participants
Interval 55.5 to 76.6
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Through Phase II completion, an average of 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Anemic response was defined as a sustained average increase in hemoglobin concentration of at least 1.5 g/dL over any rolling 12-week (84-day) period following baseline. This calculation excluded periods involving red blood cell (RBC) transfusions and was performed after applying the 14/3-day rule for valid hemoglobin assessments. The response had to be maintained through to the most recent available hemoglobin measurement for each patient.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=52 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=28 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=84 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Cohorts 1B, 2B, and Arm 3): Anemic Response Rate in Participants Who Enroll as Non-transfusion-dependent (Non-TD)
|
47.1 Percentage of Participants
Interval 32.9 to 61.5
|
21.4 Percentage of Participants
Interval 8.3 to 41.0
|
35.4 Percentage of Participants
Interval 25.0 to 47.0
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, 12 weeks (Cycle 5, Day 1), 24 weeks (Cycle 9, Day 1)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is a patient-reported questionnaire designed to measure symptom burden in participants with myeloproliferative neoplasms (MPNs). Participants rate the severity of several symptoms (such as fatigue, night sweats, itching, abdominal discomfort, bone pain, early satiety, and others) over the past 24 hours. Each symptom is scored on a scale from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be). The total score is the sum of all individual symptom scores, providing an overall measure of symptom burden. A 50% reduction in the MPN-SAF total score at 12 or 24 weeks means the patient's overall symptom burden has improved by half compared to their baseline (pre-treatment) score.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=21 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 4): Percentage of Participants Who Achieve a ≥50% Reduction From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Total Score
MPN-SAF TSS50 response at week 12
|
25.0 Percentage of Participants
Interval 8.7 to 49.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 4): Percentage of Participants Who Achieve a ≥50% Reduction From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Total Score
MPN-SAF TSS50 response at week 24
|
20.0 Percentage of Participants
Interval 5.7 to 43.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)Population: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Partial Hematological Response Rate (PHR) was defined as the proportion of participants who met the following criteria over two consecutive cycles up to the last administration of study treatment: * Platelet count \> 400-600 x 10\^9/L * WBC count within normal range (i.e., ≤ 10 x 10\^9/L) * Laboratory results confirmed after 1 cycle (after 3weeks)
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=21 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 4): Partial Hematological Response Rate (PHR)
|
38.1 Percentage of Participants
Interval 18.1 to 61.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Through Phase II completion, an average of 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Confirmed Overall Hematological Response (OHR) Rate was defined as the proportion of participants with either a confirmed complete or a partial hematological response at any time.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=21 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 4): Overall Hematological Response Rate (OHR)
|
66.7 Percentage of Participants
Interval 43.0 to 85.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Through Phase II completion, an average of 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Duration of Overall Hematological Response (OHR) Rate was defined as the time from when the overall hematological response was first met until the time at which the overall hematological response was lost, i.e., the criteria for an overall hematological response (CHR or PHR) were not observed or death occurred, whichever came first.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=21 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 4): Duration of Overall Hematological Response Rate (OHR)
|
21.1 Weeks
Interval 9.1 to 33.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Through Phase II completion, an average of 6 yearsPopulation: Intent-to-Treat (ITT) set: all screened participants who have received at least 1 dose of any study treatment component.
Rate of hemorrhagic and thromboembolic (TE) events was defined as the proportion of participants with hemorrhagic or thromboembolic events throughout the study.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=21 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 4): Rate of Hemorrhagic and Thromboembolic (TE) Events
|
61.9 Percentage of Participants
Interval 38.4 to 81.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=32 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=39 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=38 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=16 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=64 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=14 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Maximum Observed Plasma Concentration (Cmax) of Pelabresib
|
1280 ng/mL
Geometric Coefficient of Variation 29.1
|
1350 ng/mL
Geometric Coefficient of Variation 37.0
|
1210 ng/mL
Geometric Coefficient of Variation 40.0
|
1190 ng/mL
Geometric Coefficient of Variation 29.0
|
1070 ng/mL
Geometric Coefficient of Variation 26.3
|
2130 ng/mL
Geometric Coefficient of Variation 24.7
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=32 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=39 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=38 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=16 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=64 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=14 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Time to Reach Maximum Concentration (Tmax) of Pelabresib
|
1.94 Hour
Interval 0.85 to 4.02
|
1.58 Hour
Interval 0.83 to 3.63
|
1.90 Hour
Interval 0.5 to 4.0
|
1.81 Hour
Interval 0.92 to 3.13
|
1.71 Hour
Interval 0.5 to 3.87
|
2.08 Hour
Interval 1.07 to 6.0
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=31 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=37 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=36 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=16 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=63 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=12 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Pelabresib
|
120 ng/mL
Geometric Coefficient of Variation 489.0
|
201 ng/mL
Geometric Coefficient of Variation 107.0
|
244 ng/mL
Geometric Coefficient of Variation 151.0
|
162 ng/mL
Geometric Coefficient of Variation 84.0
|
240 ng/mL
Geometric Coefficient of Variation 79.1
|
174 ng/mL
Geometric Coefficient of Variation 112.0
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=32 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=39 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=38 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=16 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=64 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=14 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Pelabresib
|
5660 h*ng/mL
Geometric Coefficient of Variation 36.7
|
5610 h*ng/mL
Geometric Coefficient of Variation 35.5
|
5190 h*ng/mL
Geometric Coefficient of Variation 40.9
|
4760 h*ng/mL
Geometric Coefficient of Variation 26.7
|
4380 h*ng/mL
Geometric Coefficient of Variation 26.8
|
9590 h*ng/mL
Geometric Coefficient of Variation 28.7
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=24 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=31 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=34 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=14 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=57 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=10 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Pelabresib
|
6200 h*ng/mL
Geometric Coefficient of Variation 35.3
|
6470 h*ng/mL
Geometric Coefficient of Variation 31.7
|
5320 h*ng/mL
Geometric Coefficient of Variation 38.1
|
4930 h*ng/mL
Geometric Coefficient of Variation 28.8
|
4540 h*ng/mL
Geometric Coefficient of Variation 25.3
|
10800 h*ng/mL
Geometric Coefficient of Variation 29.0
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Tlast was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=32 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=39 Participants
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=38 Participants
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=16 Participants
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=64 Participants
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=14 Participants
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (All Arms): Time of Last Measurable Concentration (Tlast) of Pelabresib
|
7.08 Hour
Interval 4.5 to 9.0
|
7.07 Hour
Interval 2.58 to 8.08
|
7.19 Hour
Interval 6.1 to 8.05
|
7.12 Hour
Interval 7.0 to 8.17
|
7.08 Hour
Interval 5.07 to 8.58
|
7.08 Hour
Interval 5.88 to 10.08
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=30 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2A): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2A, 5 mg
|
65.9 ng/mL
Geometric Coefficient of Variation 56.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2A, 7.5 mg
|
142.0 ng/mL
Geometric Coefficient of Variation 31.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2A, 10 mg
|
108.0 ng/mL
Geometric Coefficient of Variation 29.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2A, 15 mg
|
310.0 ng/mL
Geometric Coefficient of Variation 88.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2A, 20 mg
|
325.0 ng/mL
Geometric Coefficient of Variation 37.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=30 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2A): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2A, 5 mg
|
0.92 Hour
Interval 0.5 to 2.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2A, 7.5 mg
|
1.00 Hour
Interval 0.5 to 2.02
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2A, 10 mg
|
0.76 Hour
Interval 0.5 to 1.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2A, 15 mg
|
1.55 Hour
Interval 0.67 to 3.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2A, 20 mg
|
0.53 Hour
Interval 0.33 to 1.58
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=28 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2A): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2A, 5 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2A, 7.5 mg
|
14.7 ng/mL
Geometric Coefficient of Variation 74.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2A, 10 mg
|
13.4 ng/mL
Geometric Coefficient of Variation 81.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2A, 15 mg
|
74.6 ng/mL
Geometric Coefficient of Variation 94.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2A, 20 mg
|
19.8 ng/mL
Geometric Coefficient of Variation 54.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=30 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2A, 5 mg
|
230 h*ng/mL
Geometric Coefficient of Variation 63.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2A, 7.5 mg
|
390 h*ng/mL
Geometric Coefficient of Variation 34.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2A, 10 mg
|
347 h*ng/mL
Geometric Coefficient of Variation 44.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2A, 15 mg
|
1240 h*ng/mL
Geometric Coefficient of Variation 64.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2A, 20 mg
|
829 h*ng/mL
Geometric Coefficient of Variation 42.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=26 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2A, 5 mg
|
239 h*ng/mL
Geometric Coefficient of Variation 64.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2A, 7.5 mg
|
369 h*ng/mL
Geometric Coefficient of Variation 35.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2A, 10 mg
|
375 h*ng/mL
Geometric Coefficient of Variation 47.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2A, 15 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2A, 20 mg
|
887 h*ng/mL
Geometric Coefficient of Variation 42.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=7 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2B): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2B, 5 mg
|
69.5 ng/mL
Geometric Coefficient of Variation 27.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2B, 15 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2B, 20 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 2B, 25 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=7 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2B): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2B, 5 mg
|
1.57 Hour
Interval 0.47 to 1.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2B, 15 mg
|
0.48 Hour
Not Applicable = Not calculated because pharmacokinetic profiles were incomplete or insufficient to reliably estimate summary statistics at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2B, 20 mg
|
0.53 Hour
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 2B, 25 mg
|
0.40 Hour
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=7 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2B): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2B, 5 mg
|
8.49 ng/mL
Geometric Coefficient of Variation 28.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2B, 15 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2B, 20 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 2B, 25 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=7 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2B, 5 mg
|
207 h*ng/mL
Geometric Coefficient of Variation 3.08
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2B, 15 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2B, 20 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 2B, 25 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=7 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2B, 5 mg
|
214 ng/mL
Geometric Coefficient of Variation 3.67
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2B, 15 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2B, 20 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 2B, 25 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because only a single participant contributed evaluable pharmacokinetic data at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=44 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 3): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 3, 10 mg
|
190 ng/mL
Geometric Coefficient of Variation 28.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 3, 15 mg
|
213 ng/mL
Geometric Coefficient of Variation 34.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 3, 5 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
Cohort 3, 20 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=44 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 3): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 3, 5 mg
|
0.72 Hour
Not Applicable = Not calculated because pharmacokinetic profiles were incomplete or insufficient to reliably estimate summary statistics at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 3, 10 mg
|
0.62 Hour
Interval 0.28 to 7.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 3, 15 mg
|
0.95 Hour
Interval 0.22 to 3.87
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
Cohort 3, 20 mg
|
1.25 Hour
Not Applicable = Not calculated because pharmacokinetic profiles were incomplete or insufficient to reliably estimate summary statistics at this dose level.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=43 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 3): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 3, 5 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 3, 10 mg
|
25.3 ng/mL
Geometric Coefficient of Variation 99.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 3, 15 mg
|
31.4 ng/mL
Geometric Coefficient of Variation 58.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
Cohort 3, 20 mg
|
NA ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=44 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 3, 5 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 3, 10 mg
|
519 h*ng/mL
Geometric Coefficient of Variation 54.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 3, 15 mg
|
677 h*ng/mL
Geometric Coefficient of Variation 33.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
Cohort 3, 20 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.Population: PK analysis set (PKAS): all participants in the ITT set who have received any amount of study drug and have at least one measurable study drug concentration. Only those participants contributing data at the indicated time point were analyzed.
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics.
Outcome measures
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=39 Participants
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 3, 20 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 3, 5 mg
|
NA h*ng/mL
Geometric Coefficient of Variation NA
Not Applicable = Not calculated because one or more individual plasma concentration values at this dose level were below the lower limit of quantification, resulting in non-estimable summary statistics.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 3, 10 mg
|
587 h*ng/mL
Geometric Coefficient of Variation 45.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
Cohort 3, 15 mg
|
696 h*ng/mL
Geometric Coefficient of Variation 34.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Phase 1 (24 mg Capsule PO Daily)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Phase 1 (48 mg Capsule PO Daily)
Serious events: 4 serious events
Other events: 5 other events
Deaths: 1 deaths
Phase 1 (120 mg Capsule PO Daily)
Serious events: 3 serious events
Other events: 5 other events
Deaths: 2 deaths
Phase 1 (170 mg Capsule PO Daily)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Phase 1 (230 mg Capsule PO Daily)
Serious events: 2 serious events
Other events: 3 other events
Deaths: 1 deaths
Phase 1 (300 mg Capsule PO Daily)
Serious events: 4 serious events
Other events: 4 other events
Deaths: 1 deaths
Phase 1 (400 mg Capsule PO Daily)
Serious events: 6 serious events
Other events: 7 other events
Deaths: 1 deaths
Phase 1 (225 mg Tablet PO Daily)
Serious events: 6 serious events
Other events: 8 other events
Deaths: 1 deaths
Phase 1 (275 mg Tablet PO Daily)
Serious events: 6 serious events
Other events: 6 other events
Deaths: 1 deaths
Phase 1 (Overall)
Serious events: 33 serious events
Other events: 44 other events
Deaths: 8 deaths
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1A
Serious events: 18 serious events
Other events: 48 other events
Deaths: 6 deaths
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1B
Serious events: 23 serious events
Other events: 50 other events
Deaths: 3 deaths
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2A
Serious events: 29 serious events
Other events: 58 other events
Deaths: 3 deaths
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2B
Serious events: 18 serious events
Other events: 28 other events
Deaths: 3 deaths
Phase 2 - Arm 3 (Combination Treatment Arm for JAKi-Naïve MF Participants)
Serious events: 40 serious events
Other events: 84 other events
Deaths: 7 deaths
Phase 2 - Arm 4 (Monotherapy Arm for Essential Thrombocythemia (ET))
Serious events: 5 serious events
Other events: 21 other events
Deaths: 0 deaths
Phase 2 (Overall)
Serious events: 133 serious events
Other events: 289 other events
Deaths: 22 deaths
Serious adverse events
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=3 participants at risk
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=5 participants at risk
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=5 participants at risk
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=3 participants at risk
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=3 participants at risk
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=4 participants at risk
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
n=7 participants at risk
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
n=8 participants at risk
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
n=6 participants at risk
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (Overall)
n=44 participants at risk
Phase 1 (Overall): All treated patients in Phase 1
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1A
n=48 participants at risk
In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1B
n=52 participants at risk
In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2A
n=59 participants at risk
In Phase 2 (Arm 2) - Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2B
n=28 participants at risk
In Phase 2 (Arm 2) - Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 3 (Combination Treatment Arm for JAKi-Naïve MF Participants)
n=84 participants at risk
Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily.
Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 4 (Monotherapy Arm for Essential Thrombocythemia (ET))
n=21 participants at risk
Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 (Overall)
n=292 participants at risk
Phase 2 (Overall): All treated patients in Phase 2
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Investigations
Blood creatinine increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
5/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
11/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.5%
9/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Leukostasis syndrome
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Splenic infarction
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Splenomegaly
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Acute left ventricular failure
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Cardiac iron overload
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Chronic coronary syndrome
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Dilated cardiomyopathy
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Left ventricular failure
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Pericarditis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Right ventricular failure
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Endocrine disorders
Adrenal haematoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Endocrine disorders
Inappropriate antidiuretic hormone secretion
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Abdominal wall haematoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Duodenal ulcer haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Intestinal haematoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
50.0%
3/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Asthenia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Chest pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Chills
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Disease progression
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Drug withdrawal syndrome
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Fatigue
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Malaise
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Oedema
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Pyrexia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Hepatobiliary disorders
Biliary dilatation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Hepatobiliary disorders
Hepatocellular injury
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Immune system disorders
Serum sickness
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Abscess limb
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Aspergillus infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Bronchiolitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Bronchopulmonary aspergillosis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
COVID-19
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Dermo-hypodermitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Device related infection
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Device related sepsis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Empyema
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Endocarditis bacterial
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Enterococcal bacteraemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Escherichia bacteraemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Escherichia infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Fournier's gangrene
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Herpes simplex reactivation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Influenza
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Localised infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Nocardiosis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
18/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pneumonia acinetobacter
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pneumonia bacterial
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pneumonia pneumococcal
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pneumonia staphylococcal
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Post procedural infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pyelonephritis acute
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Septic shock
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Streptococcal sepsis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Tooth infection
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Viral infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Extradural haematoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blast cell count increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.4%
5/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haematopoietic neoplasm
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive breast carcinoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratoacanthoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic squamous cell carcinoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma of the skin
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal squamous cell carcinoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian neoplasm
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of head and neck
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transformation to acute myeloid leukaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Brain stem haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Spinal cord compression
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Superior sagittal sinus thrombosis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Suicide attempt
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Renal cyst ruptured
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Renal haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Organising pneumonia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Cutaneous vasculitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Aortic dissection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Haematoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Peripheral ischaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
Other adverse events
| Measure |
Phase 1 (24 mg Capsule PO Daily)
n=3 participants at risk
Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (48 mg Capsule PO Daily)
n=5 participants at risk
Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (120 mg Capsule PO Daily)
n=5 participants at risk
Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (170 mg Capsule PO Daily)
n=3 participants at risk
Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (230 mg Capsule PO Daily)
n=3 participants at risk
Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (300 mg Capsule PO Daily)
n=4 participants at risk
Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (400 mg Capsule PO Daily)
n=7 participants at risk
Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (225 mg Tablet PO Daily)
n=8 participants at risk
Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (275 mg Tablet PO Daily)
n=6 participants at risk
Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 1 (Overall)
n=44 participants at risk
Phase 1 (Overall): All treated patients in Phase 1
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1A
n=48 participants at risk
In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 1 (MF Participants Previously Treated With JAK Inhibitor Monotherapy) - Cohort 1B
n=52 participants at risk
In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2A
n=59 participants at risk
In Phase 2 (Arm 2) - Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 2 (Supplement to JAK Inhibitor Combination Arm for MF Participants) - Cohort 2B
n=28 participants at risk
In Phase 2 (Arm 2) - Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 3 (Combination Treatment Arm for JAKi-Naïve MF Participants)
n=84 participants at risk
Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily.
Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 - Arm 4 (Monotherapy Arm for Essential Thrombocythemia (ET))
n=21 participants at risk
Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.
|
Phase 2 (Overall)
n=292 participants at risk
Phase 2 (Overall): All treated patients in Phase 2
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
57.1%
4/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
27.3%
12/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
35.4%
17/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.8%
15/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
30.5%
18/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
48.8%
41/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.9%
99/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
11/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.9%
10/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.5%
16/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Spleen disorder
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
37.5%
18/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
23.1%
12/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
42.4%
25/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
32.1%
9/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
38.1%
32/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
32.9%
96/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Blood and lymphatic system disorders
Thrombocytosis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Angina pectoris
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Hyperdynamic left ventricle
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
14/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Ear and labyrinth disorders
Ear discomfort
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Ear and labyrinth disorders
Ear haemorrhage
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.1%
12/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Eye disorders
Eye haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Eye disorders
Vision blurred
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.5%
6/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
18/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
6/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
10/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.2%
6/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
8/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.5%
13/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.1%
44/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
6/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.9%
11/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.2%
11/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.5%
13/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
6/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.8%
52/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.5%
6/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.1%
11/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.3%
30/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Anal incontinence
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.9%
11/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
26.9%
14/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.3%
9/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.4%
6/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
32.1%
27/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
47.6%
10/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
26.4%
77/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Diarrhoea
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
100.0%
4/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
42.9%
3/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
62.5%
5/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
38.6%
17/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
31.2%
15/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
50.0%
26/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
57.6%
34/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
64.3%
18/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
47.6%
40/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
47.6%
10/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
49.0%
143/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
7/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
13/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Gingival pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Nausea
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
60.0%
3/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
80.0%
4/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
100.0%
3/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
50.0%
2/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
62.5%
5/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
52.3%
23/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
37.5%
18/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
44.2%
23/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
35.6%
21/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
42.9%
12/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
31.0%
26/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
76.2%
16/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
39.7%
116/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Oral disorder
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
14/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
42.9%
3/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
50.0%
3/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
29.5%
13/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.6%
7/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
10/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.9%
10/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
8/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
15/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
42.9%
9/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.2%
59/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Asthenia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.8%
9/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
8/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
7/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.3%
30/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Chest pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Chills
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.4%
6/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.9%
10/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.2%
21/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Early satiety
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
11/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Fatigue
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
60.0%
3/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
80.0%
4/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
71.4%
5/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
37.5%
3/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
45.5%
20/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
29.2%
14/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
32.7%
17/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.0%
13/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
46.4%
13/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
32.1%
27/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
23.8%
5/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
30.5%
89/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Gait disturbance
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Influenza like illness
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
13/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Malaise
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Nodule
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
5/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.5%
16/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Oedema peripheral
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
60.0%
3/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
2/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.5%
9/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
27.1%
13/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.4%
8/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.3%
12/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.4%
6/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
12/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.5%
51/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Peripheral swelling
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
General disorders
Pyrexia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.4%
5/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
8/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.5%
6/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
8/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.4%
6/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
14/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.1%
44/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
11/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
COVID-19
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
6/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.5%
6/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.3%
9/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
24/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.8%
52/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.1%
12/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Cystitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Eye infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Folliculitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Herpes simplex reactivation
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
14/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.6%
31/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Hordeolum
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Influenza
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Localised infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Nasopharyngitis
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.9%
10/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
18/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
13/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Orchitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Otitis media
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
8/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.2%
21/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Septic shock
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.5%
6/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.5%
16/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Skin infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.5%
6/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.6%
11/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
8/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
14/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.7%
43/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.4%
5/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.5%
7/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.2%
6/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
14/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.4%
39/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Infections and infestations
Urinary tract infection bacterial
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.3%
9/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.3%
9/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
8/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
16/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.4%
48/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
10/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
9/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.3%
33/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Nail injury
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Procedural site reaction
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Vascular access site complication
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blast cell count increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.4%
5/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.4%
6/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
8/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.2%
24/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
5/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.2%
24/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Bilirubin conjugated increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
13/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
20/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.1%
11/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.6%
25/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blood phosphorus increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Cardiac murmur
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Electrocardiogram QRS complex abnormal
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Haematocrit increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
International normalised ratio increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Platelet count decreased
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
2/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.2%
8/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.4%
5/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.4%
8/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.6%
11/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
8/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
26.2%
22/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
56/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Transaminases increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Troponin T increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Weight decreased
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
50.0%
3/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.4%
5/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.8%
9/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
26.9%
14/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
8/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.4%
39/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
Weight increased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
60.0%
3/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
62.5%
5/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.9%
18/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.6%
7/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
13/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.0%
13/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
15/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.2%
59/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Folate deficiency
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.4%
5/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
2/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
6/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.6%
5/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
15/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.4%
5/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.5%
22/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
2/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
6/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.4%
5/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.4%
8/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.2%
27/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
11/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.1%
12/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
2/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.1%
11/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
20/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Iron overload
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
4/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
10/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.6%
11/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
21/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
56/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.6%
7/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.6%
5/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
8/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.2%
17/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.1%
44/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Bone cyst
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.5%
7/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
8/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
8/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.6%
28/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Gouty arthritis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.5%
7/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.9%
7/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
35.7%
10/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.4%
18/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
6/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.1%
50/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.6%
5/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.9%
7/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
20/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.1%
12/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal disorder
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.5%
6/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.9%
10/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.3%
30/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.5%
7/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
8/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
32.1%
9/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
15/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.0%
41/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Ageusia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
6/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Dizziness
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.6%
7/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
10/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.0%
13/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
5/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
21/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.5%
60/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
37.5%
3/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.5%
9/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.8%
10/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
30.8%
16/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
27.1%
16/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
21/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
42.9%
9/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
27.1%
79/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Headache
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
40.0%
2/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
2/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.2%
8/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
6/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
26.9%
14/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.2%
6/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.6%
19/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
28.6%
6/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.5%
54/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Migraine
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Myoclonus
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
17/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Nervous system disorders
Taste disorder
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Anxiety
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Confusional state
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
4/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.3%
7/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.5%
22/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.5%
5/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
15/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
5/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
13/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Reproductive system and breast disorders
Genital lesion
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
6/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
18.8%
9/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.2%
11/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.0%
13/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
50.0%
14/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
26.2%
22/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
73/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
22.9%
11/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.2%
10/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.3%
9/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
23.8%
20/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.9%
58/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.7%
8/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
37.5%
3/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.6%
6/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
6/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.5%
7/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.9%
10/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
32.1%
9/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
15.5%
13/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.1%
47/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
1/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.8%
3/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.2%
6/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
17.9%
5/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
9/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.9%
26/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.2%
3/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.1%
12/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
13/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus pain
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.2%
6/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
15/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.0%
3/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
3/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.4%
5/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.5%
7/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.2%
6/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
12/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
11.0%
32/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
2/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.8%
10/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
42.3%
22/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
25.0%
7/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.4%
18/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
3/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
21.2%
62/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.2%
2/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
13.5%
7/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
4/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
8.9%
26/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.68%
2/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
10/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.6%
1/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Skin induration
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.8%
2/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
6.0%
5/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
19.0%
4/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
15/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.4%
2/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
2/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
3.1%
9/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.3%
1/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.34%
1/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Flushing
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.4%
4/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Haematoma
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
66.7%
2/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
10.7%
3/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
4/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.1%
12/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Hot flush
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.5%
2/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.9%
1/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.7%
1/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
2/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
4.8%
1/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
6/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
33.3%
1/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
14.3%
1/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.1%
1/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.7%
4/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
7.1%
6/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.5%
2/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.5%
16/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
20.0%
1/5 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/3 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/4 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/7 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
12.5%
1/8 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
16.7%
1/6 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
9.1%
4/44 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/48 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.8%
3/52 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
5.1%
3/59 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/28 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
1.2%
1/84 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
0.00%
0/21 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
2.4%
7/292 • Adverse events were collected for each participant from the first dose of study treatment through 30 days after the last dose of pelabresib (CPI-0610). The duration of adverse event collection varied by participant and phase, with a maximum follow-up of approximately 2 years in Phase I and approximately 8 years in Phase II. Deaths were collected for each participant from study initiation through study completion, with an average follow-up of up to approximately 10 years.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
- Publication restrictions are in place
Restriction type: OTHER